title: Response to: Letter to the Editor Regarding the Article "Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma".
authors.affiliation: 1 Department of Endocrinology, Memorial Sloan Kettering Cancer Center , New York, New York.
authors.forename: Laura
authors.initials: L
authors.lastname: Boucai
authors.affiliation: 2 Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center , New York, New York.
authors.forename: Laura Y
authors.initials: LY
authors.lastname: Wang
authors.affiliation: 3 Medical School, University of Rochester , Rochester, New York.
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Smith
authors.affiliation: 2 Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center , New York, New York.
authors.forename: Frank L
authors.initials: FL
authors.lastname: Palmer
authors.affiliation: 1 Department of Endocrinology, Memorial Sloan Kettering Cancer Center , New York, New York.
authors.forename: Azhar
authors.initials: A
authors.lastname: Mahrous
authors.affiliation: 1 Department of Endocrinology, Memorial Sloan Kettering Cancer Center , New York, New York.
authors.forename: R Michael
authors.initials: RM
authors.lastname: Tuttle
authors.affiliation: 1 Department of Endocrinology, Memorial Sloan Kettering Cancer Center , New York, New York.
authors.forename: James A
authors.initials: JA
authors.lastname: Fagin
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000097:blood* / Q000150:complications*; D013964:Thyroid Neoplasms / Q000097:blood* / Q000150:complications*; D013972:Thyrotropin / Q000037:antagonists & inhibitors*
chemical_list: D013972:Thyrotropin